Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-29
2007-05-29
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266310, C544S287000, C544S289000
Reexamination Certificate
active
10937958
ABSTRACT:
Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides quinazolinone, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders (e.g., migraine, ataxia, Parkinson's disease, bipolar disorders, trigeminal neuralgia, spasticity, mood disorders, brain tumors, psychotic disorders, myokymia, seizures, epilepsy, hearing and vision loss, Alzheimer's disease, age-related memory loss, learning deficiencies, anxiety and motor neuron diseases, maintaining bladder control or treating urinary incontinence) and as neuroprotective agents (e.g., to prevent stroke and the like) by modulating potassium channels associated with the onset or recurrence of the indicated conditions.
REFERENCES:
patent: 2002/0128277 (2002-09-01), Dworetzky et al.
patent: WO01/92283 (2001-12-01), None
Bajaj, et al. Arzneimittel-Forschung (2003), 53(7), pp. 480-485.
Archana et al., Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2002), 41B(11), pp. 2371-2373.
El-Helby et al., Al-Azhar Journal of Pharmaceutical Sciences (2001), vol. 28, pp. 73-88.
Al-Sehemi et al., Chemical Communications (2001), vol. 24, pp. 2684-2685.
Srivastava et al., Asian Journal of Chemistry (2000), vol. 12, pp. 243-246.
Abdel-Gawad et al., Bulletin of the Faculty of Pharmarcy (Cairo Univ.) (1995), vol. 33, pp. 67-74.
Bajaj et al. Arzneim.-Forsch./Drug Res., vol. 53(7), p. 480-485 (2003).
Mohamed, M.M., “Reactions of 3-amino-2-propyl-4(3H)-quinazolinone with aromatic aldehydes, nitrogen nucleophiles, and esters”,Chemical Abstract(1983) vol. 99, Abstract #38433 (CAPLUS Accession No. 1983:438433).
Varnavas, A., et al. “Quinazolinone derivatives: synthesis and binding evaluation on cholecystokinin receptors”,Chemical Abstract(1996), vol. 125, Abstract #75354 (CAPLUS Accession No. 1996:377707).
Desai, N.C., et al. “Synthesis of substituted quinazolone derivatives as potential anti-HIV agents”, Part III.,Chemical Abstract, (1996) vol. 125, Abstract #75356 (CAPLUS Accession No. 1996:377710).
Klosa, J. “Synthesis of amides in the quinazolone series.”,Chemical Abstract(1966) vol. 65, Abstract #12304 (CAPLUS Accession No. 1966:412304).
Buu-Hoi, N.P., et al. “Synthesis and pharmacological properties of urethane and urea derivatives of heterocyclic amines”,Chemical Abstract(1966) vol. 65, Abstract #12305 (CAPLUS Accession No. 1966:412305).
Amato George Salvatore
McNaughton-Smith Grant Andrew
Thomas, Jr. James Barnwell
Grazier Nyeemah
Icagen Inc.
McKane Joseph K.
Townsend and Townsend / and Crew LLP
LandOfFree
Fused ring heterocycles as potassium channel modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused ring heterocycles as potassium channel modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused ring heterocycles as potassium channel modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3730586